Thanks for making it easy for us with all the hard work you are doing out there! Can’t wait to kick your ass again 1st Week of September!
Sigurdur Oli Olafsson, Hikma Pharmaceuticals PLC - CEO & Executive Director
" So I think, first of all, I'm a little bit different than the CEO of Amarin. So I don't comment on my expectation on the results of a judge. I think I'm not qualified in any way. I'm not a lawyer in any way. So for me to comment on that, I think, will be highly inappropriate to say the least. We're going to have the oral argument through phones on September 2. And we expect that the results could come as early as fourth quarter, maybe more likely in first quarter of next year, could be at the latest in the second quarter of next year. Also, it's interesting that the CEO of Amarin seems to know so much more than I do about the supply of the generics. And he also had a very deep understanding but we were surprised when the outcome of the legal case in Nevada, which he also commented. So I don't have the same understanding as he has. As I've said, I already have a supply ready to go to the market. If I would decide today, I could launch such risk. So we have a supply ready to launch at risk. We're also building the inventory to be able to take a fair market share in the market. But I'm not going to share with Amarin what my intended market share, that also depends on the other generics. If anyone else talked already, so anyone will be approved before the decision by the appeals court. So overall, I think on operating margin, what I've said, we expect a little bit lower margin in the beginning. We -- and we've been very open about that. But also we need to keep in mind that there is plenty of API suppliers today. When Amarin was originally developed this product, there was a limited supply. Where today, there's much more supply of the API than Amarin had in the beginning. So I think that is a very different situation. So -- but I can't comment on the thoughts that the CEO of Amarin has. It's just over and above my pay grade to do that. "
Sigurdur Oli Olafsson, Hikma Pharmaceuticals PLC - CEO & Executive Director
" So I think, first of all, I'm a little bit different than the CEO of Amarin. So I don't comment on my expectation on the results of a judge. I think I'm not qualified in any way. I'm not a lawyer in any way. So for me to comment on that, I think, will be highly inappropriate to say the least. We're going to have the oral argument through phones on September 2. And we expect that the results could come as early as fourth quarter, maybe more likely in first quarter of next year, could be at the latest in the second quarter of next year. Also, it's interesting that the CEO of Amarin seems to know so much more than I do about the supply of the generics. And he also had a very deep understanding but we were surprised when the outcome of the legal case in Nevada, which he also commented. So I don't have the same understanding as he has. As I've said, I already have a supply ready to go to the market. If I would decide today, I could launch such risk. So we have a supply ready to launch at risk. We're also building the inventory to be able to take a fair market share in the market. But I'm not going to share with Amarin what my intended market share, that also depends on the other generics. If anyone else talked already, so anyone will be approved before the decision by the appeals court. So overall, I think on operating margin, what I've said, we expect a little bit lower margin in the beginning. We -- and we've been very open about that. But also we need to keep in mind that there is plenty of API suppliers today. When Amarin was originally developed this product, there was a limited supply. Where today, there's much more supply of the API than Amarin had in the beginning. So I think that is a very different situation. So -- but I can't comment on the thoughts that the CEO of Amarin has. It's just over and above my pay grade to do that. "